NVAX logo

Novavax (NVAX)

Profile

Full Name

Novavax, Inc.

Ticker Symbol

NVAX

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

December 5, 1995

Indexes

Not included

Website

http://www.novavax.com

Employees

952

Key Details

Price

$6.63(+0.23%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$682.16M(+22.61% YoY)

Annual EPS

-$1.23(+77.26% YoY)

PE ratio

2.50

Next earnings date

Aug 8, 2025

Next ex-dividend date

N/A

Next split date

N/A

Quick Search

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    See Full Chart & Historical Data

    Analyst ratings

    Price

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Current Price

    $6.63
    NVAX price is $6.63

    30-Day Relative Volume

    1.16
    NVAX 30-day relative volume is 1.16

    Price Performance

    Price Today change

    +0.23%
    NVAX price is up +0.23% today

    Price YTD change

    -17.6%
    NVAX price is down -17.6% since January 1st

    Price 1-year change

    -48.92%
    NVAX price is down -48.92% year-on-year

    Price 3-year change

    -88.41%
    NVAX price is down -88.41% over the past 3 years

    Price Range

    Price All-time high

    $331.68
    NVAX price is currently -98.00% below its historical high of $331.68

    Price 3-year low

    $3.53
    NVAX price is currently +87.68% above its 3-year low

    Capitalization

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Market cap

    Market cap

    $1.07B
    NVAX market capitalization is $1.07 billion

    Market cap 3-year change

    -75.98%
    NVAX market capitalization is down -75.98% over the past 3 years

    Market cap All-time high

    $22.99B
    NVAX market capitalization is currently -95.33% below its historical high of $22.99 billion

    Market cap sector rank

    76.6%
    NVAX market capitalization is higher than 76.6% of companies in Healthcare sector

    Shares Outstanding

    Shares Outstanding 1-Year Change

    +1.3%
    NVAX shares outstanding is up +1.3% year-on-year

    Shares Outstanding 3-Year Change

    +107.21%
    NVAX shares outstanding is up +107.21% over the past 3 years

    Technical Indicators

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Beta

    1.25
    NVAX beta is 1.25

    200-day SMA

    $8.48
    NVAX price is currently -21.87% below its 200-day simple moving average

    50-day SMA

    $6.75
    NVAX price is currently -1.83% below its 50-day simple moving average

    RSI

    47.94
    NVAX 14-day relative strength index is 47.94

    Volume

    1.16
    NVAX 30-day relative volume is 1.16

    ATR

    $0.38
    NVAX average true range is $0.38

    10-day Historical Volatility

    54.89%
    NVAX 10-day historical volatility is 54.89%

    Dividend

    Income Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Revenue

    Revenue

    $682.16M
    NVAX annual revenue is $682.16 million

    Revenue Analysts estimate

    $1.03B
    NVAX annual revenue is currently -33.88% lower than the consensus analysts' forecast

    Revenue 1-year change

    +22.61%
    NVAX annual revenue is up +22.61% year-on-year

    Revenue Sector rank

    76.95%
    NVAX annual revenue is higher than 76.95% of companies in Healthcare sector

    EPS

    EPS

    -$1.23
    NVAX annual earnings per share is -$1.23

    EPS Analysts estimate

    $2.56
    NVAX annual earnings per share is currently -148.14% lower than the consensus analysts' forecast

    EPS 1-year change

    +77.26%
    NVAX annual earnings per share is up +77.26% year-on-year

    EPS Sector rank

    50.82%
    NVAX annual earnings per share is higher than 50.82% of companies in Healthcare sector

    Profit

    Gross profit

    $479.42M
    NVAX annual gross profit is $479.42 million

    Gross margin

    70.28%
    NVAX annual gross profit margin is 70.28%

    Operating profit

    -$248.93M
    NVAX annual operating income is -$248.93 million

    Operating margin

    -36.49%
    NVAX annual operating profit margin is -36.49%

    Net income

    -$187.50M
    NVAX annual net profit is -$187.50 million

    Net margin

    -27.49%
    NVAX annual net profit margin is -27.49%

    Expenses

    Total expenses

    $931.09M
    NVAX annual total expenses is $931.09 million

    Operating expenses

    $728.35M
    NVAX annual total operating expenses is $728.35 million

    Cost of goods sold

    $202.74M
    NVAX annual cost of goods sold is $202.74 million

    Selling, general & administrative expenses

    $337.19M
    NVAX annual SGA is $337.19 million

    Depreciation and amortization

    $48.50M
    NVAX annual depreciation & amortization is $48.50 million

    Interest expense

    $20.07M
    NVAX annual interest expense is $20.07 million

    Income tax

    $10.88M
    NVAX annual income tax is $10.88 million

    EBIT & EBITDA

    EBIT

    -$156.54M
    NVAX annual earnings before interest & taxes is -$156.54 million

    EBITDA

    -$108.04M
    NVAX annual EBITDA is -$108.04 million

    Balance Sheet

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Assets

    Total assets

    $1.56B
    NVAX annual total assets is $1.56 billion

    Non current assets

    $431.48M
    NVAX annual long term assets is $431.48 million

    Current assets

    $1.13B
    NVAX annual total current assets is $1.13 billion

    Cash and cash equivalents

    $530.23M
    NVAX annual cash & cash equivalents is $530.23 million

    Accounts receivable

    $108.28M
    NVAX annual accounts receivable is $108.28 million

    Inventory

    $8.75M
    NVAX annual inventory is $8.75 million

    Liabilities

    Total liabilities

    $2.18B
    NVAX annual total liabilities is $2.18 billion

    Long term liabilities

    $1.03B
    NVAX annual total long term liabilities is $1.03 billion

    Current liabilities

    $1.15B
    NVAX annual total current liabilities is $1.15 billion

    Accounts payable

    $41.58M
    NVAX annual accounts payable is $41.58 million

    Debt

    Total debt

    $230.42M
    NVAX annual total debt is $230.42 million

    Total debt 1-year change

    +0.58%
    NVAX annual total debt is up +0.58% year-on-year

    Long term debt

    $223.41M
    NVAX annual long term debt is $223.41 million

    Short term debt

    $7.01M
    NVAX annual short term debt is $7.01 million

    Equity & Capital

    Shareholders equity

    -$623.84M
    NVAX annual stockholders equity is -$623.84 million

    Book value

    -$623.84M
    NVAX annual book value is -$623.84 million

    Retained earnings

    -$5.01B
    NVAX annual retained earnings is -$5.01 billion

    Working capital

    -$25.47M
    NVAX annual working capital is -$25.47 million

    Cash Flow Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Cashflow Activities

    Cash from operations

    -$87.26M
    NVAX annual cash flow from operations is -$87.26 million

    Cash from operations 1-year change

    +87.78%
    NVAX annual cash flow from operations is up +87.78% year-on-year

    Cash from investing

    -$204.04M
    NVAX annual cash flow from investing activities is -$204.04 million

    Cash from investing 1-year change

    -246.97%
    NVAX annual cash flow from investing activities is down -246.97% year-on-year

    Cash from financing

    $260.58M
    NVAX annual cash flow from financing activities is $260.58 million

    Cash from financing 1-year change

    +5734.82%
    NVAX annual cash flow from financing activities is up +5734.82% year-on-year

    CAPEX

    CAPEX

    $14.64M
    NVAX annual capital expenditures is $14.64 million

    CAPEX 1-year change

    -75.11%
    NVAX annual capital expenditures is down -75.11% year-on-year

    Free Cash Flow

    Free cash flow

    -$101.90M
    NVAX annual free cash flow is -$101.90 million

    Free cash flow 1-year change

    +86.81%
    NVAX annual free cash flow is up +86.81% year-on-year

    Profitability Ratios

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Margins

    Gross margin

    70.28%
    NVAX annual gross profit margin is 70.28%

    Operating margin

    -36.49%
    NVAX annual operating profit margin is -36.49%

    Net margin

    -27.49%
    NVAX annual net profit margin is -27.49%

    ROA & ROE

    ROA

    -11.17%
    NVAX annual return on assets is -11.17%

    ROE

    30.06%
    NVAX annual return on equity is 30.06%

    Valuation

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    PE Ratio

    PE ratio

    2.50
    NVAX price to earnings ratio is 2.50

    PE ratio Sector rank

    5.61%
    NVAX price to earnings ratio is higher than 5.61% of companies in Healthcare sector

    PB Ratio

    PB ratio

    -14.19
    NVAX price to book ratio is -14.19

    PB ratio Sector rank

    3.11%
    NVAX price to book ratio is higher than 3.11% of companies in Healthcare sector

    PS Ratio

    PS ratio

    0.88
    NVAX price to sales ratio is 0.88

    PS ratio Sector rank

    23.05%
    NVAX price to sales ratio is higher than 23.05% of companies in Healthcare sector

    Enterprise value

    Enterprise value

    $1.04B
    NVAX enterprise value is $1.04 billion

    Enterprise value Sector rank

    75.33%
    NVAX enterprise value is higher than 75.33% of companies in Healthcare sector

    EV/EBITDA

    EV/EBITDA

    1.87
    NVAX EV/EBITDA is 1.87

    EV/EBITDA Sector rank

    76.48%
    NVAX EV/EBITDA is higher than 76.48% of companies in Healthcare sector

    Financial Health

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Liquidity

    Current ratio

    0.98
    NVAX annual current ratio is 0.98

    Quick ratio

    0.97
    NVAX annual quick ratio is 0.97

    Leverage

    Debt to equity

    -0.27
    NVAX annual debt to equity ratio is -0.27

    Interest coverage ratio

    -7.80
    NVAX annual interest coverage ratio is -7.80

    Risk & Stability

    Piotroski F-Score

    5
    NVAX piotroski f-score is 5

    Altman Z-Score

    -4.11
    NVAX altman z-score is -4.11

    Analyst ratings

    Recent major analysts updates

    May 9, 25 JP Morgan
    Underweight
    Dec 10, 24 HC Wainwright & Co.
    Buy
    Nov 13, 24 HC Wainwright & Co.
    Buy
    Nov 12, 24 HC Wainwright & Co.
    Buy
    Aug 12, 24 JP Morgan
    Underweight
    Aug 12, 24 B. Riley Securities
    Buy
    Aug 2, 24 B. Riley Securities
    Buy
    Jul 30, 24 JP Morgan
    Underweight
    Jun 14, 24 B of A Securities
    Neutral
    May 23, 24 B. Riley Securities
    Buy

    Institutional Ownership

    Screeners with NVAX included

    Growing Shares Outstanding
    US stocks
    Stocks with high beta
    Stocks below SMA 200
    Most recommended stocks
    Best performing stocks last 3 months
    NASDAQ Dividend Calendar
    Stocks below analysts price target
    Healthcare sector
    All stocks
    • What is the ticker symbol for Novavax?
    • Does Novavax pay dividends?
    • What sector is Novavax in?
    • What industry is Novavax in?
    • What country is Novavax based in?
    • When did Novavax go public?
    • Is Novavax in the S&P 500?
    • Is Novavax in the NASDAQ 100?
    • Is Novavax in the Dow Jones?
    • When was Novavax's last earnings report?
    • When does Novavax report earnings?
    • Should I buy Novavax stock now?

    What is the ticker symbol for Novavax?

    The ticker symbol for Novavax is NASDAQ:NVAX

    Does Novavax pay dividends?

    No, Novavax does not pay dividends

    What sector is Novavax in?

    Novavax is in the Healthcare sector

    What industry is Novavax in?

    Novavax is in the Biotechnology industry

    What country is Novavax based in?

    Novavax is headquartered in United States

    When did Novavax go public?

    Novavax's initial public offering (IPO) was on December 5, 1995

    Is Novavax in the S&P 500?

    No, Novavax is not included in the S&P 500 index

    Is Novavax in the NASDAQ 100?

    No, Novavax is not included in the NASDAQ 100 index

    Is Novavax in the Dow Jones?

    No, Novavax is not included in the Dow Jones index

    When was Novavax's last earnings report?

    Novavax's most recent earnings report was on May 8, 2025

    When does Novavax report earnings?

    The next expected earnings date for Novavax is Aug 8, 2025

    Should I buy Novavax stock now?

    As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
    On this page